Ardelyx (NASDAQ:ARDX) Sets New 52-Week Low - Here's Why
Ardelyx (NASDAQ:ARDX) shares recently hit a new 52-week low of $3.86, closing at $3.89, amid mixed analyst opinions and a missed quarterly earnings report. The biopharmaceutical company reported a $0.07-per-share loss against an anticipated $0.05 loss, with revenue slightly below estimates. Despite some downgrades, the consensus analyst rating remains "Moderate Buy" with a target price of $13.90, and institutional investors hold nearly 59% of the company's stock.
Ardelyx (ARDX) Following Strong Results And Guidance Still Looks Undervalued
Ardelyx (ARDX) recently reported strong Q2 2026 results with higher revenue and narrower net losses, along with updated full-year guidance, yet its stock price has fallen significantly. Despite the recent dip, Simply Wall St assesses Ardelyx as undervalued, with a fair value of $16.33 against its current price of $3.92, driven by expanding markets for its key drugs IBSRELA and XPHOZAH. However, the company faces risks related to its dependence on these two products and reimbursement uncertainties.
Exploring 3 High Growth Tech Stocks In The US Market
The article identifies three high-growth tech stocks in the US market: Ardelyx (ARDX), Madrigal Pharmaceuticals (MDGL), and Syndax Pharmaceuticals (SNDX). It highlights their impressive revenue and earnings growth projections, strategic financial moves, and commitment to innovation, despite some currently operating unprofitably. The US market itself has seen a 19% increase over the past year with an expected 17% annual earnings growth.
Ardelyx Leads The Charge With These 3 Compelling Penny Stocks
This article highlights three penny stocks – Ardelyx (ARDX), Harte Hanks (HHS), and BrightSpire Capital (BRSP) – that offer intriguing growth opportunities. It details each company's financial health, recent performance, market capitalization, and specific challenges or strategic moves, such as Ardelyx's revenue growth, Harte Hanks' merger plans, and BrightSpire Capital's dividend yield. The piece emphasizes that these stocks present chances for substantial returns when backed by strong fundamentals, despite the inherent risks of the penny stock market.
Ardelyx Chief Commercial Officer Announces Upcoming Resignation
Ardelyx (ARDX) announced that its Chief Commercial Officer, Eric Foster, will resign effective August 28, 2026, to pursue a new role. The resignation is amicable and not due to disagreements with Ardelyx. Analysts currently rate ARDX as a "Buy" with a $15.00 price target, while TipRanks' AI Analyst, Spark, rates it as "Neutral" due to financial quality concerns despite strong product revenue growth.
Exploring 3 High Growth Tech Stocks In The US Market
This article identifies three high-growth tech stocks in the US market: Ardelyx (ARDX), Madrigal Pharmaceuticals (MDGL), and Syndax Pharmaceuticals (SNDX). It provides an overview of each company's operations, financial performance, and growth projections, highlighting their potential for profitability within three years. The article also includes a list of top 10 high-growth tech companies and emphasizes the importance of innovation and strategic investments in R&D for sustained expansion.
ARDX Reiterates by Wedbush -- Price Target Maintained at $9.00
Wedbush has reiterated an 'Outperform' rating for Ardelyx (ARDX), maintaining a $9.00 price target despite recent price target adjustments by other analysts. The company's stock is considered undervalued with a GF Value™ of $8.69 compared to its current price of $4.06, though it faces challenges with unprofitability and notable insider selling activity. Investors are advised to perform thorough due diligence given the mixed signals from financial metrics and institutional/insider actions.
Ardelyx Leads The Charge With These 3 Compelling Penny Stocks
This article highlights three penny stocks – Ardelyx (ARDX), Harte Hanks (HHS), and BrightSpire Capital (BRSP) – that offer intriguing growth opportunities. It details their financial health, recent performance, and market capitalization, emphasizing their potential for substantial returns despite typical penny stock challenges. Each company's overview includes key financial figures, operational insights, and noteworthy strategic developments.
ARDX Maintained by Piper Sandler -- Price Target Lowered to $15.00
Piper Sandler has maintained its "Overweight" rating for Ardelyx (ARDX) but reduced the price target from $16.00 to $15.00, reflecting a cautious outlook despite the stock appearing 53.2% undervalued by GuruFocus' GF Value™. The company shows strong growth potential but struggles with profitability and valuation, alongside mixed guru sentiment and insider selling activity. Investors are advised to conduct thorough research given these factors.
Ardelyx, Inc. Announces Resignation of Eric Foster from Chief Commercial Officer, Effective August 28, 2026
Ardelyx, Inc. announced that Eric Foster has resigned from his position as Chief Commercial Officer, effective August 28, 2026. Foster is leaving to pursue a new opportunity with a pre-commercial company, and his departure is not due to any disagreements with Ardelyx.
AIGH Capital Management LLC Buys Shares of 3,200,000 Ardelyx, Inc. $ARDX
AIGH Capital Management LLC acquired 3,200,000 shares of Ardelyx, Inc. (NASDAQ:ARDX) in the second quarter, making it their 17th largest holding. Other institutional investors also increased their stakes in Ardelyx, while company insiders recently sold shares. Ardelyx reported a quarterly EPS miss and revenue below analyst estimates, leading several analysts to reduce their price targets while maintaining "buy" ratings for the biopharmaceutical company.
Rubric Capital discloses 6.56% Ardelyx (ARDX) stake totaling 16.2M shares
Rubric Capital Management LP and David Rosen have reported a 6.56% passive ownership stake in Ardelyx, Inc., amounting to 16,202,700 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, with Rubric Capital Master Fund LP having rights to dividends and sale proceeds for over 5% of the common stock. The ownership percentage is based on Ardelyx's 247,029,387 shares outstanding as of April 23, 2026.
ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx
SueWallSt, powered by Levi & Korsinsky LLP, has announced an investigation into potential securities law violations concerning Ardelyx (ARDX). This comes after Ardelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August 6, 2026, due to payer utilization-management restrictions, causing shares to fall nearly 18%. Investors who suffered losses after purchasing ARDX shares are encouraged to contact SueWallSt for a no-cost review of their potential claims.
ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx
SueWallSt has initiated an investigation into potential securities law violations by Ardelyx (NASDAQ: ARDX) following a significant drop in its stock price. The company lowered its 2026 IBSRELA revenue guidance by up to $80 million and withdrew its long-term XPHOZAH revenue target, citing payer utilization-management restrictions. This guidance cut led to an almost 18% decline in Ardelyx shares on August 7, 2026, prompting concerns about the adequacy of its disclosures regarding payer coverage.
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)
Levi & Korsinsky has announced an investigation into Ardelyx (ARDX) following a significant 17.86% stock drop on August 7, 2026. This decline occurred after the company reported second-quarter 2026 product revenue and earnings per share that were below consensus estimates, and subsequently lowered its full-year IBSRELA revenue guidance. The firm is encouraging investors who suffered losses to contact them for a review of potential securities law violations.
Ardelyx (ARDX) Is Down 19.1% After ESOP Shelf Filing And Higher 2026 Product Revenue Guidance
Ardelyx (ARDX) experienced a 19.1% stock drop following a US$36 million shelf registration for an ESOP and its Q2 earnings report. Despite a net loss, the company raised its 2026 IBSRELA revenue guidance to US$350–370 million, while reiterating XPHOZAH revenue expectations. This move signals management's confidence in its core products but also indicates a plan to secure additional equity capital amidst ongoing losses and market access uncertainties.
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)
Levi & Korsinsky is investigating potential securities law violations on behalf of Ardelyx (NASDAQ: ARDX) shareholders after the company's shares fell by 17.86% following a Q2 earnings report that missed consensus estimates and led to lowered full-year revenue guidance. The firm encourages investors who suffered losses to request a review of their holdings. This notice details the investigation, eligibility criteria, and how shareholders can participate without upfront costs.
Ardelyx Q2 revenue up 31% but guidance cut due to payer issues, hold rating maintained
Ardelyx reported a 31% year-over-year revenue increase in Q2, driven by strong demand for IBSRELA and XPHOZAH. However, the company cut its revenue guidance to $350-$370 million due to "payer friction" limiting near-term growth. Management is working to address access challenges, and the company expects profitability by 2027, with future valuation dependent on resolving these issues.
Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story (NASDAQ:ARDX)
Ardelyx, Inc. maintains a "hold" rating due to near-term execution uncertainty despite strong demand for IBSRELA and XPHOZAH. Q2 revenue growth was significant, but payer friction led to a guidance cut, prompting management to enhance reimbursement teams, optimize pharmacy networks, and expand the sales force. The company trades at a discount on revenue multiples, with profitability targeted for 2027, contingent on resolving access issues and sustaining growth.
Ardelyx, Inc. (ARDX) interactive stock chart
This page provides an interactive stock chart and financial information for Ardelyx, Inc. (ARDX) on Yahoo Finance. It displays real-time stock prices, after-hours trading data, and a list of recent news articles related to the company's financial performance and stock analysis. The content also includes related tickers and market indices.
Is Ardelyx (ARDX) Undervalued Following Q2 Results And Updated Product Guidance?
Ardelyx (ARDX) is under pressure despite reporting higher Q2 2026 revenue and a narrower net loss, with its stock down significantly in recent months. However, analysts suggest the company is undervalued, with a consensus price target of $16.33 against a current price of $4.00, driven by expectations of strong revenue growth and future profitability from its IBSRELA and XPHOZAH products. Investors are weighing the potential for growth against dilution risks from a recent shelf registration filing.
Ardelyx (ARDX): Millennium entities and Israel Englander report 5.7% stake in 13G/A
Investment entities affiliated with Millennium, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have reported a 5.7% beneficial ownership stake in Ardelyx, Inc. This disclosure, made via a Schedule 13G/A filing, indicates shared voting and dispositive power over 14,200,773 shares. Integrated Core Strategies (US) LLC, also part of this group, separately reported a 4.8% stake, or 12,030,115 shares, in Ardelyx common stock.
HC Wainwright Estimates Ardelyx's Q3 Earnings (NASDAQ:ARDX)
HC Wainwright has lowered its Q3 2026 EPS estimate for Ardelyx (NASDAQ:ARDX) to a loss of $0.06 per share, down from a projected profit of $0.05, while maintaining a "Buy" rating and a $13 price target. This adjustment follows Ardelyx's Q2 earnings report, where the company posted a loss of $0.07 per share, missing consensus estimates, despite revenue increasing by 34.3% year-over-year to $120.88 million. Despite the revised forecast, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a $15 price target.
3 High Growth Stocks With Healthy Balance Sheets Retail Investors May Be Missing
This article identifies three high-growth stocks with healthy balance sheets that retail investors might be overlooking: Ardelyx (ARDX), Dutch Bros (BROS), and Unity Software (U). These companies are highlighted for their strong projected earnings growth while maintaining solid financial positions, according to an analysis derived from Simply Wall St's "Healthy high growth potential" screener. The piece details each company's operations, market cap, and key growth drivers, alongside potential risks, encouraging investors to explore them further.
Unity Stock And 2 High Growth Picks Worth Watching Now
This article identifies three high-growth potential stocks—Ardelyx (ARDX), Dutch Bros (BROS), and Unity Software (U)—that are worth watching due to their solid earnings growth expectations and balance sheet profiles, despite current market uncertainties driven by inflation. Each company is analyzed for its operations, market cap, and specific financial and market factors that make it an interesting prospect for investors. The article emphasizes that while these companies show promise, they also come with inherent risks like execution challenges and valuation concerns.
Citigroup Lowers Ardelyx (NASDAQ:ARDX) Price Target to $11.00
Citigroup has lowered its price target for Ardelyx (NASDAQ:ARDX) from $14.00 to $11.00 but maintained a "buy" rating, suggesting a significant upside. Despite this, other analysts have also recently adjusted their price targets, and the company's latest earnings report showed revenue growth but missed EPS expectations with continued negative margins. Ardelyx, a biopharmaceutical company, focuses on treatments for cardio-renal and gastrointestinal diseases.
3 Financially Strong Penny Stocks Worth A Closer Look
This article identifies three financially strong penny stocks – Ardelyx (ARDX), Alkane Resources (ASX:ALK), and Taboola.com (TBLA) – that warrant further research. These companies were filtered using a "Financially Fit Penny Stocks" screener, highlighting their resilience amidst market uncertainties. Each profile discusses the company's business model, financial potential, and key risks for investors to consider.
Ardelyx Stock Leads These Financially Fit Penny Stocks Worth A Closer Look
This article highlights three financially fit penny stocks – Ardelyx (ARDX), Taboola.com (TBLA), and Hyliion Holdings (HYLN) – that offer potential growth and resilience in a shifting interest rate environment. Each company is presented with its market position, growth prospects, and associated risks, emphasizing their balance sheet strength. The article suggests these stocks as starting points for investors interested in small-cap companies with strong fundamentals.
Ardelyx, Inc. Stock 12‑Month Price Target Cut to $13, Implies 167% Upside
Ardelyx, Inc.'s stock 12-month price target has been reduced from $16.3 to $13 by analysts, though this still suggests a 167% potential upside based on its recent closing price. Despite the target cut, the consensus rating from 11 analysts remains a "Buy," with no "Hold" or "Sell" recommendations. Investors can find more detailed analyst data and recommendations for Ardelyx, Inc. on TradingView's Forecasts tab and News Flow.
Ardelyx (ARDX) Stock Slides As Payer Friction Clouds Growth Path
Ardelyx stock dropped 17.9% to US$4, extending a three-month slide after Q2 product revenue reached US$118 million, primarily from IBSRELA. The company faces challenges including lowered 2026 IBSRELA guidance due to payer access hurdles and confirmed Medicare bundling for XPHOZAH, impacting long-term growth targets. While 2027 profitability is reaffirmed, rising expenses and reliance on key products highlight ongoing risks.
Ardelyx Inc (ARDX) (Q2 2026) Earnings Call Highlights: Record Revenue of $118M Driven by Strong ...
Ardelyx Inc (ARDX) reported record quarterly revenue of $118 million in Q2 2026, a 31% year-over-year increase, fueled by strong demand for both Ibsrela and Xphozah. Despite this growth, the company lowered its full-year 2026 Ibsrela revenue guidance to $350-$370 million due to significant payer hurdles and withdrew its $750 million Xphozah guidance, citing market uncertainty. Ardelyx remains on track for sustainable profitability in 2027 and is actively addressing market access challenges through expanded sales efforts and strategic initiatives.
Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates
Ardelyx (ARDX) reported a Q2 loss of $0.07 per share, which missed the Zacks Consensus Estimate of a $0.05 loss, and revenues of $120.88 million, falling short of estimates by 2.27%. The company's shares have underperformed the market year-to-date, and its unfavorable estimate revisions trend has resulted in a Zacks Rank #4 (Sell). Investors are now looking to management's commentary and future earnings outlook for insights into the stock's performance.
Ardelyx Inc earnings missed by $0.04, revenue fell short of estimates
Ardelyx Inc (NASDAQ: ARDX) reported a second-quarter EPS of $-0.070, missing the analyst estimate of $-0.030 by $0.04. The company's revenue for the quarter was $118.1M, falling short of the consensus estimate of $125.68M. Ardelyx Inc's stock has decreased by 28.170% in the last three months and 6.530% in the last twelve months, with its financial health rated as "good performance" by InvestingPro.
Earnings Flash (ARDX) Ardelyx, Inc. Reports Q2 Revenue $120.9M, vs. FactSet Est of $121.0M
Ardelyx, Inc. (ARDX) reported its Q2 revenue at $120.9 million, slightly below FactSet's estimate of $121.0 million. The company's stock shows a 5-day change of -0.81% and a year-to-date change of -16.47%. Ardelyx is a commercial-stage biopharmaceutical company focused on innovative medicines, including IBSRELA and XPHOZAH.
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
Ardelyx (Nasdaq: ARDX) announced its second quarter 2026 financial results, reporting record combined revenue of $118.1 million, a 31% year-over-year increase, driven by strong performances from IBSRELA and XPHOZAH. Despite increased utilization management from payors affecting IBSRELA revenues, the company updated its full-year 2026 revenue guidance for IBSRELA to $350-$370 million and reiterated XPHOZAH guidance at $110-$120 million, aiming for profitability in 2027. Ardelyx also provided updates on its pipeline, including the ACCEL Phase 3 trial for IBSRELA in chronic idiopathic constipation and the development of RDX10531.
ARDX: Q2 2026 revenue up 31% to $118.1M; net loss narrows, guidance updated for market shifts
Ardelyx, Inc. (ARDX) reported a 31% year-over-year revenue increase to $118.1 million in Q2 2026, driven by IBSRELA and XPHOZAH sales. The company's net loss narrowed to $16.7 million, and cash reserves increased to $281.8 million. Ardelyx also updated its full-year 2026 guidance to reflect current market dynamics.
Ardelyx earnings on deck: Can biotech sustain revenue surge?
Ardelyx Inc. is set to report second-quarter earnings, with analysts expecting a narrower loss and significant revenue growth. Investors will focus on the sustainability of its commercial execution for products like IBSRELA and XPHOZAH, alongside the company's path to profitability given recent downward revisions in earnings estimates. Updates on pipeline progress for IBSRELA and RDX10531 could also provide crucial insights.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
Faruqi & Faruqi, LLP is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who suffered losses exceeding $100,000 between October 31, 2023, and July 1, 2024. The investigation centers on allegations that Ardelyx made misleading statements regarding its intent to include XPHOZAH in TDAPA, which led to a significant stock price drop when the company announced it would not apply. Investors have until October 15, 2024, to seek the role of lead plaintiff in the federal securities class action.
Renaissance Technologies LLC Sells 522,352 Shares of Ardelyx, Inc. $ARDX
Renaissance Technologies LLC significantly reduced its stake in Ardelyx, Inc. (NASDAQ:ARDX) by selling 522,352 shares, retaining 1.27 million shares valued at $7.6 million. Despite this, institutional investors and hedge funds still own a substantial 58.92% of the company. Ardelyx shares opened at $4.98, below key moving averages, with analysts maintaining a "Moderate Buy" consensus rating and a $15.73 price target, despite some recent downgrades.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
Faruqi & Far
Ardelyx Inc (ARDX) News, Articles, Events & Latest Updates
This article compiles recent news and updates concerning Ardelyx Inc (ARDX), highlighting its stock performance, recent financial reports, analyst ratings, and significant events. It covers topics like earnings expectations, a Medicare reimbursement battle, insider transactions, and commentary on the company's path to profitability. The news indicates mixed signals for the company, with some positive developments but also concerns from analysts.
How Investors Are Reacting To Ardelyx (ARDX) Rising Revenues Amid Growing Analyst Earnings Caution
Ardelyx (ARDX) is experiencing rising quarterly revenues and a smaller loss per share, yet analysts are becoming more cautious, cutting earnings estimates. This creates a tension between the company's operational progress and analyst confidence in near-term earnings. The article discusses how this might influence Ardelyx's investment narrative, especially concerning reimbursement risks for its products XPHOZAH and IBSRELA.
How Investors Are Reacting To Ardelyx (ARDX) Rising Revenues Amid Growing Analyst Earnings Caution
Ardelyx (ARDX) is experiencing rising quarterly revenues and a narrowing loss per share, even as analysts express caution by cutting earnings estimates due to uncertainties surrounding market access and reimbursement for its key products, XPHOZAH and IBSRELA. The company has reiterated its 2026 revenue guidance, but the tension between operational improvements and analyst skepticism is influencing its investment narrative, with some forecasting significant long-term growth while others remain wary of regulatory and payer risks. Investors are encouraged to consider diverse perspectives and conduct their own research on Ardelyx's financial health and future prospects.
Ardelyx Number of Employees 2026 | Employee Count & Headcount Data
Ardelyx, Inc. (NASDAQ: ARDX) had approximately 508 employees worldwide as of March 2026, representing a 139.4% growth from 212 employees in 2023. The company is actively hiring, with 127 active job postings in 2026, an 85.4% increase from 2025. Ardelyx is headquartered in Waltham, Massachusetts, and its workforce is primarily concentrated in the United States.
Ardelyx Inc (ARDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Ardelyx Inc (ARDX), detailing its price momentum, support and resistance levels, and various technical indicators. It notes that ARDX ranks 373 out of 385 in the Biotechnology & Medical Research industry for price momentum and is currently trading between a resistance level of $5.45 and a support level of $4.83. The analysis presents a mix of neutral and sell signals from different indicators and moving averages, resulting in an overall neutral signal.
Ardelyx Inc (ARDX) Institutional Confidence
Ardelyx Inc (ARDX) has a current institutional shareholding score of 7.00, placing it 80th out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 71.25%, which is a quarter-over-quarter decrease of 7.13%. Steven Cohen is the largest institutional shareholder, holding 2.90M shares, representing 1.21% of shares outstanding.
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
Faruqi & Faruqi, LLP is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) following a federal securities class action lawsuit. Investors who suffered losses exceeding $100,000 between October 31, 2023, and July 1, 2024, are encouraged to contact the firm. The lawsuit alleges that Ardelyx made misleading statements regarding its intent to apply for XPHOZAH inclusion in TDAPA, which it later decided against, causing a significant drop in stock price.
Ardelyx Inc (ARDX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Ardelyx Inc (ARDX), identifying its major institutional investors and their proportional holdings. It also provides a breakdown of shareholder types and traces institutional shareholding over recent quarters, highlighting changes in shares held and proportions. Additionally, the report lists various ETFs that include ARDX in their portfolios.
ARDX|Ardelyx Inc|Price:5.030|Chg%:-0.100
This article provides a detailed financial overview of Ardelyx Inc. (ARDX), including its latest earnings, revenue, EPS, and analyst ratings. It presents a comprehensive data dashboard with quarterly and annual breakdowns of the company's income statement, balance sheet, and cash flow statement, designed for investor analysis. The financial indicators cover various metrics such as net profit, gross margin, debt-to-assets ratio, and return on equity, along with frequently asked questions regarding the company's financial performance.
Ardelyx (ARDX) Faces A Valuation Test, Is The Discount Too Wide?
Ardelyx (ARDX) is currently trading at a significant discount to analyst targets and intrinsic value estimates, with a fair value estimate of $16.33 against its current share price of $5.03. This undervaluation is supported by the growing prevalence of chronic kidney disease and gastrointestinal disorders, which expands the market for Ardelyx's key products, IBSRELA and XPHOZAH. However, the company faces risks due to its concentrated reliance on these two products and uncertainties surrounding Medicare coverage for XPHOZAH.
